• 1
    Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127: 1592622.
  • 2
    Soykan I, Sivri B, Sarosiek I, Kierran B, McCallum RW. Demography, clinical characteristics, psychological profiles, treatment and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998; 43: 2398404.
  • 3
    Revicki DA, Rentz AM, Dubois D et al. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res 2004; 13: 83344.
  • 4
    Farup CE, Williams GR, Leidy NK, Helbers L, Murray M, Quigley EMM. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care 1998; 21: 1699706.
  • 5
    Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol 1999; 94: 102933.
    Direct Link:
  • 6
    Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 175680.
  • 7
    Horowitz M, Harding PE, Maddox AF et al. Gastric and oesophageal emptying in insulin-dependent diabetes mellitus. J Gastroenterol Hepatol 1986; 1: 97113.
  • 8
    Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001; 24: 12649.
  • 9
    Stanghellini V, Tosetti C, Paternico A et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996; 110: 103642.
  • 10
    Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003; 98: 7838.
    Direct Link:
  • 11
    Delgado-Aros S, Camilleri M, Cremonini F, Ferber I, Stephens D, Burton DD. Contributions of gastric volumes and gastric emptying to meals size and postmeal symptoms in functional dyspepsia. Gastroenterology 2004; 127: 168594.
  • 12
    Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 1986; 90: 191925.
  • 13
    Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology 1986; 91: 949.
  • 14
    Karamanolis G, Arts J, Caenepeel P, Verbeke K, Janssens J, Tack J. Determinants of symptom pattern in idiopathic gastroparesis: gastric emptying or proximal stomach dysfunction. Gastroenterology 2005; 128: A547 (abstract).
  • 15
    Samsom M, Salet GAM, Roelofs JMM, Akkermans LM, Vanberge-Henegouwen GP, Smout AJ. Compliance of the proximal stomach and dyspeptic symptoms in patients with type 1 diabetes mellitus. Dig Dis Sci 1995; 40: 203742.
  • 16
    Bredenoord AJ, Chial HJ, Camilleri M, Mullan BP, Murray JA. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003; 1: 26472.
  • 17
    Revicki DA, Rentz AM, Dubois D et al. Development and validation of a patient-assessed gastroparesis symptoms severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther 2003; 18: 14150.
  • 18
    Parrish CR, Yoshida C. Nutrition intervention for the patient with gastroparesis: an update. Pract Gastroenterol 2005; 29: 2935.
  • 19
    Emerson AP. Foods high in fiber and phytobezoar formation. J Am Diet Assoc 1987; 87: 16757.
  • 20
    Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999; 60: 4227.
  • 21
    McCallum TW, Ricci DA, Rakatansky H et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983; 6: 4637.
  • 22
    Ricci D, Saltzman M, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol 1985; 7: 2532.
  • 23
    Snape WJ, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus. Ann Intern Med 1982; 96: 4446.
  • 24
    Chen JDZ, Pan J, McCallum RW. Clinical significance of gastric myoelectrical dysrhythmias. Dig Dis 1995; 13: 27590.
  • 25
    McCallum RW, Valenzuela G, Polepalle S. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J Pharmacol Exp Ther 1991; 258: 13642.
  • 26
    Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993; 153: 146975.
  • 27
    Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc 2004; 44: 6615.
  • 28
    Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999; 94: 12304.
  • 29
    Silvers D, Kipnes M, Broadstone V et al. Domperidone in the management of symptoms of diabetic gastroparesis; efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. Clin Ther 1998; 20: 43853.
  • 30
    Koch KL, Stern RM, Stewart WR, Vasey MW. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol 1989; 84: 106975.
  • 31
    Soykan I, Lin Z, Jones S, Chen J, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997; 12: 9527.
  • 32
    Sawant P, Das HS, Desai N, Kalokhe S, Patil S. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia. J Assoc Physicians India 2004; 52: 6268.
  • 33
    Basque J-R, Noritake M, Mizogami H, Katsura Y. Efficacy of itopride hydrochloride on gastric emptying in patients with diabetic gastroparesis. Gastroenterology 2005; 128: A156 (abstract).
  • 34
    Farrugia G, Macielaq M, Peeters TL, Sarr MG, Galdes A, Szurszewski JH. Motilin and OHM-11526 activate a calcium current in human and canine jejunal circular smooth muscle. Am J Physiol 1997; 36: G40412.
  • 35
    Weber FH, Richard RE, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993; 88: 48590.
  • 36
    Moshiree B, Gupta V, Verne GN, Toskes PP. Azithromycin: a new therapy for gastroparesis. Gastroenterology 2005; 128: A547 (abstract).
  • 37
    Kendall BJ, Chakravarti A, Kendall E, Soykan L, McCallum RW. The effect of intravenous erythromycin on solid meal gastric emptying in patients with chronic symptomatic post-vagotomy antrectomy gastroparesis. Aliment Pharmacol Ther 1997; 11: 3815.
  • 38
    Parkman HP, Pagano AP, Vozzelli M, Ryan JP. The gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in the rabbit stomach. Am J Physiol 1995; 269: G41826.
  • 39
    Parkman HP, Pagano AP, Ryan JP. Erythromycin inhibits pyloric muscle by releasing nitric oxide and VIP through neuronal motilin receptors. Gastroenterology 1996; 111: 68290.
  • 40
    Coulie B, Tack J, Peeters T, Janssens J. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut 1998; 43: 395400.
  • 41
    Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003; 98: 25963.
  • 42
    Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993; 88: 2037.
  • 43
    Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351: 108996.
  • 44
    Talley NJ, Verlinden M, Snape W et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying. A randomized double-blind placebo controlled trial. Aliment Pharmacol Ther 2000; 14: 16536.
  • 45
    Talley NJ, Verlinden M, Geenen DJ et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomized, double-blind, placebo controlled trial. Gut 2001; 49: 395401.
  • 46
    McCallum RW, Rogel R, Fang JC, Altman RS, Faichney JD, Goldstein BJ. Mitemacil fumarate (GM-611) provided symptomatic relief of diabetic gastroparesis, especially in type I diabetics: results of a 12-week, multi-center, double-blind, placebo-controlled, randomized phase 2b study. Gastroenterology 2005; 128: A467 (abstract).
  • 47
    Murray CD, Martin NM, Patterson M et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double-blind, placebo-controlled, cross-over study. Gut 2005; 54: 16938.
  • 48
    Tack J, Depoortere I, Bisschops R, Verbeke K, Janssens J, Peeters T. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005; 22: 84753.
  • 49
    Fraser RJ, Horowitz M, Maddox AF, Dent J. Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis – effects of cisapride. Gut 1994; 35: 1728.
  • 50
    Braden B, Enghofer M, Schaub M, Usadel KH, Caspary WJ, Lembcke B. Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control. Aliment Pharmacol Ther 2002; 16: 13416.
  • 51
    Abell TL, Camilleri M, DiMagno EP, Hench VS, Zinsmeister AR, Malagelada JR. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991; 36: 61620.
  • 52
    Jones MP. Access options for withdrawn motility-modifying agents. Am J Gastroenterol 2002; 97: 21848.
    Direct Link:
  • 53
    Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 4638.
  • 54
    Degen L, Matzinger D, Merz M et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 174551.
  • 55
    Tougas G, Chen Y, Luo D, Salter J, D'Elia T, Earnest DL. Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms. Gastroenterology 2003; 124: A54 (abstract).
  • 56
    Morganroth J, Ruegg PC, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 2002; 97: 23217.
    Direct Link:
  • 57
    Kanaizumi T, Nakano H, Matsui Y et al. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 1991; 41: 3357.
  • 58
    Asakawa H, Hayashi I, Fukui T, Tokunaga K. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract 2003; 61: 17582.
  • 59
    Potet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 2001; 299: 100712.
  • 60
    Malagelada JR, Rees WD, Mazzotta LJ, Go VL. Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: effect of metoclopramide and bethanechol. Gastroenterology 1980; 78: 28693.
  • 61
    McCallum RW, Fink SM, Lerner E, Berkowitz DM. Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients. Gastroenterology 1983; 84: 15737.
  • 62
    Parkman HP, Trate DM, Knight LC, Brown KL, Maurer AH, Fisher RS. Cholinergic effects on human gastric motility. Gut 1999; 45: 34654.
  • 63
    Kishibayashi N, Karasawa A. Effects of KW-5092 on antroduodenal coordination and gastric emptying in guinea pigs. J Pharm Pharmacol 1998; 50: 104550.
  • 64
    Ueki S, Seiki M, Yoneta T et al. Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther 1003; 264: 1527.
  • 65
    McCallum R, Zarling E, Goetsch CA et al. Nizatidine controlled release has gastric prokinetic effects in patients with gastroesophageal reflux disease (GERD). Gastroenterology 2004; 126(Suppl. 2): A-335.
  • 66
    Rosa-e-Silva L, Troncon LE, Oliveira RB, Iazigi N, Gallo L Jr, Foss MC. Treatment of diabetic gastroparesis with oral clonidine. Aliment Pharmacol Ther 1995; 9: 17983.
  • 67
    Huilgol V, Evans J, Hellman RS, Soergel KH. Acute effect of clonidine on gastric emptying in patients with diabetic gastropathy and controls. Aliment Pharmacol Ther 2002; 16: 94550.
  • 68
    Lossos IS, Mevorach D, Oren R. Thiethylperazine treatment of gastroparesis diabeticorum. Ann Pharmacother 1992; 26: 1016.
  • 69
    Kranke P, Morin AM, Roewer N et al. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2002; 95: 13343.
  • 70
    Hurwitz A, Robinson RG, Herrin WF, Christie J. Oral anticholinergics and gastric emptying. Clin Pharmacol Ther 1982; 31: 16874.
  • 71
    Jaup BH, Dotevall G. The effect of pirenzipine and L-hyoscyamine on gastric emptying and salivary secretion in healthy volunteers. Scand J Gastroenterol 1981; 16: 76973.
  • 72
    Kranke P, Morin AM, Roewer N, Eberhart LH. Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: a meta-analysis of randomized controlled trials. Acta Anaesthesiol Scand 2002; 46: 23844.
  • 73
    Kothari SN, Boyd WC, Bottcher ML, Lambert PJ. Antiemetic efficacy of prophylactic dimenhydrinate vs. ondansetron: a randomized, prospective trial in patients undergoing laparoscopic cholecystectomy. Surg Endosc 2000; 14: 9269.
  • 74
    Stewart JJ, Wood MJ, Wood CD, Mims ME. Effects of motion sickness and antimotion sickness drugs on gastric function. J Clin Pharmacol 1994; 34: 63543.
  • 75
    El-Gammal A, Rashed HM, Taylor J, Werkman R, Abell TL. Long term ondansetron therapy is beneficial in patients with chronic nausea and vomiting. Gastroenterology 2000; 118: A1170 (abstract).
  • 76
    Netzer P, Gaia C, Lourens ST et al. Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers? Aliment Pharmacol Ther 2002; 16: 11927.
  • 77
    Nielsen OH, Hvid-Jacobsen K, Lund P, Langoholz E. Gastric emptying and subjective symptoms of nausea: lack of effect of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion 1990; 46: 8996.
  • 78
    Stacher G, Bergmann H, Schneider C et al. Effects of the 5-HT3 receptor antagonist ICS 205–930 on fat-delayed gastric emptying and antral motor activity. Br J Clin Pharmacol 1990; 30: 418.
  • 79
    McCallum RW, Soykan I, Sridhar KR et al. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999; 13: 7780.
  • 80
    Adelhoj B, Petring OU, Brynnum J et al. Effect of diazepam on drug absorption and gastric emptying in man. Br J Anaesth 1985; 57: 11079.
  • 81
    Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004; 64: 77794.
  • 82
    Diemunsch P, Schoeffler P, Bryssine B et al. Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth 1999; 82: 2746.
  • 83
    Prakash C, Lustman PJ, Freedland KE, Clouse RE. Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients. Dig Dis Sci 1998; 43: 19516.
  • 84
    Sawhney MS, Prakash C, Lustman PJ, Clouse RE. Tricyclic antidepressants for persistent or recurrent vomiting in diabetic patients. Gastroenterology 2001; 120: A243 (abstract).
  • 85
    Gupta YK, Sharma M. Reversal of pyrogallol-induced delay in gastric emptying in rats by ginger (Zingiber officinale). Methods Find Exp Clin Pharmacol 2001; 23: 5013.
  • 86
    Gonlachanvit S, Chen YH, Hasler WL et al. Ginger reduces hyperglycemia-evoked gastric dysrhythmias in healthy humans: possible role of endogenous prostaglandins. J Pharmacol Exp Ther 2003; 307: 1098103.
  • 87
    Roscoe JA, Morrow GR, Hickok JT et al. The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 2003; 26: 73142.
  • 88
    Wang L. Clinical observation on acupuncture treatment in 35 cases of diabetic gastroparesis. J Tradit Chin Med 2004; 24: 1635.
  • 89
    Rathmann W, Enck P, Frieling T, Gries FA. Visceral afferent neuropathy in diabetic gastroparesis. Diabetes Care 1991; 14: 10869.
  • 90
    Hasler WL, Soudah HC, Dulai G, Owyang C. Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostaglandins. Gastroenterology 1995; 108: 72736.
  • 91
    Pimentel M, Sam C, Lin HC. Indomethacin improves symptoms and electrogastrographic findings in patients with gastric dysrhythmias. Neurogastroenterol Motil 2001; 13: 422 (abstract).
  • 92
    Simonian HP, Parkman HP. Effect of prostaglandin inhibition with ketorolac on gastric activity and dyspeptic symptoms in patients with dyspeptic symptoms. Am J Gastroenterol 2003; 98(Suppl.): S58.
  • 93
    Gorelick AB, Koshy SS, Hooper FG et al. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998; 2756: G4606.
  • 94
    Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 10918.
  • 95
    Chial HJ, Camilleri M, Burton D, Thomforde G, Olden KW, Stephens D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003; 284: G1307.
  • 96
    Gorard DA, Libby GW, Farthing MJ. 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut 1994; 35: 496500.
  • 97
    Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 2004; 61: 16073.
  • 98
    Carroll DG, Kline KM, Malnar KF. Role of topiramate for the treatment of painful diabetic peripheral neuropathy. Pharmacotherapy 2004; 24: 118693.
  • 99
    Malcom A, Camilleri M, Kost L et al. Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function. Aliment Pharmcol Ther 2000; 14: 78393.
  • 100
    Maurer AH, Krevsky B, Knight LC, Brown K. Opioid and opioid-like drug effects on whole-gut transit measured by scintigraphy. J Nucl Med 1996; 37: 81822.
  • 101
    Mercadante S, Casuccio A, Fulfaro F et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19: 2898904.
  • 102
    Tawfik MO, Bryuzgin V, Kourteva G, FEN-INT-20 Study Group. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin 2004; 20: 25967.
  • 103
    Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002; 23: 4853.
  • 104
    Foss JF. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg 2001; 182: 19S26S.
  • 105
    Gonenne J, Camilleri M, Ferber I et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005; 3: 78491.
  • 106
    Talley NJ, Weaver AL, Zinmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995; 40: 5849.
  • 107
    Cutts TF, Abell TL, Karas JG, Kuns J. Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia. Dig Dis Sci 1996; 41: 136978.
  • 108
    Clouse RE, Lustman PJ. Gastrointestinal symptoms in diabetic patients: lack of association with neuropathy. Am J Gastroenterol 1989; 84: 86872.
  • 109
    Drossman DA, Talley NJ, Leserman J, Olden KW, Barriero MA. Sexual and physical abuse in gastrointestinal illness. Review and recommendations. Ann Intern Med 1995; 123: 78294.
  • 110
    Cutts TF, Luo J, Starkebaum W, Rashid H, Abell TL. Gastric electrical stimulation is superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term healthcare benefits. Neurogastroenterol Motil 2005; 17: 3543.
  • 111
    Wagner EH, Glasgow RE, Davis C et al. Quality improvement in chronic illness care: a collaborative approach. J Jt Comm Health Care Qual 2001; 27: 6380.
  • 112
    Rashed H, Cutts T, Luo J et al. Predictors of response to a behavioral treatment in patients with chronic gastric motility disorders. Dig Dis Sci 2002; 47: 10206.
  • 113
    Horowitz M, Edelbroek M, Fraser R, Maddox A, Wishart J. Disordered gastric motor function in diabetes mellitus. Recent insights into prevalence, pathophysiology, clinical relevance, and treatment. Scand J Gastroenterol 1991; 26: 67384.
  • 114
    Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus. Arch Intern Med 2001; 161: 198996.
  • 115
    Maleki D, Locke GR III, Camilleri M et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000; 160: 280816.
  • 116
    Ziegler D, Schadewaldt P, Pour Mirza A et al. [13C]octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: validation and relationship to gastric symptoms and cardiovascular autonomic function. Diabetologia 1996; 39: 82330.
  • 117
    Talley NJ. Diabetic gastropathy and prokinetics. Am J Gastroenterol 2003; 98: 2741.
    Direct Link:
  • 118
    Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 67580.
  • 119
    Oster-Jorgensen E, Pedersen SA, Larsen ML. The influence of induced hyperglycaemia on gastric emptying rate in healthy humans. Scand J Clin Lab Invest 1990; 50: 8316.
  • 120
    Jebbink RJ, Samsom M, Bruijs PP et al. Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type I diabetes mellitus. Gastroenterology 1994; 107: 13907.
  • 121
    Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995; 109: 75565.
  • 122
    Barnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology 1988; 94: 73944.
  • 123
    Hasler WL, Soudah HC, Kulai G, Owyang C. Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostaglandins. Gastroenterology 1995; 108: 72736.
  • 124
    Jones KL, Horowitz M, Berry M, Wishart JM, Guha S. Blood glucose concentration influences postprandial fullness in IDDM. Diabetes Care 1997; 20: 11416.
  • 125
    Petrakis IE, Chalkiadakis G, Vrachassotakis N, Sciacca V, Vassilakis SJ, Xynos E. Induced-hyperglycemia attenuates erythromycin-induced acceleration of hypertonic liquid-phase gastric emptying in type I diabetic patients. Dig Dis Sci 1999; 17: 2417.
  • 126
    Jones KL, Berry M, Kong MF, Kwiatek MA, Samsom M, Horowitz M. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 1999; 22: 33944.
  • 127
    Gentilcore D, O'Donovan D, Jones KL, Horowitz M. Nutrition therapy for diabetic gastroparesis. Curr Diab Rep 2003; 35: 41826.
  • 128
    Lehmann R, Honegger RA, Feinle C, Freid M, Spinas GA, Schwizer W. Glucose control is not improved by accelerating gastric emptying in patients with type 1 diabetes and gastroparesis, a pilot study with cisapride as a model drug. Exp Clin Endocrinol Diabetes 2003; 111: 25561.
  • 129
    Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 30806.
  • 130
    Shopbell JM, Hopkins B, Shronts EP. Nutrition screening and assessment. In: GottschlichM, ed. The Science and Practice of Nutrition Support: A Case-based Core Curriculum. Dubuque: Kendall/Hunt, 2001: 119130.
  • 131
    Parrish CR, Krenitsky J, McCray S. University of Virginia Health System Nutrition Support Traineeship Syllabus. 2003. Available at: (accessed 25 January 2006).
  • 132
    McCray S, Walker S, Parrish CR. Much ado about refeeding. Pract Gastroenterol 2005; 29: 268.
  • 133
    Gupta P, Rao SS. Attenuation of isolated pyloric pressure waves in gastroparesis in response to botulinum toxin injection: a case report. Gastrointest Endosc 2002; 56: 7702.
  • 134
    Lacy BE, Crowell MD, Schettler-Duncan A, Mathis C, Pasricha PJ. The treatment of diabetic gastroparesis with botulinum toxin injection into the pylorus. Diabetes Care 2004; 27: 23417.
  • 135
    Lacy BE, Zayat EN, Crowell MD, Schuster MM. Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am J Gastroenterol 2002; 97: 154852.
    Direct Link:
  • 136
    Miller LS, Szych GA, Kantor SB et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 2002; 97: 165360.
    Direct Link:
  • 137
    Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc 2002; 55: 9203.
  • 138
    Arts J, Van Gool S, Caenepeel P, Janssens J, Tack J. Effect of intrapyloric injection of botulinum toxin on gastric emptying and meal-related symptoms in gastroparesis. Gastroenterology 2003; 124: A53 (abstract).
  • 139
    Bromer MQ, Friedenberg F, Miller LS, Fisher RS, Swartz K, Parkman HP. Endoscopic pyloric injection of botulinum toxin A for treatment of refractory gastroparesis. Gastrointest Endosc 2005; 61: 8339.
  • 140
    Coleski R, Hasler W. Clinical and gastric functional predictors of symptom response to pyloric injection of botulinum toxin in patients with gastroparesis. Neurogastroenterol Motil 2005; 17: 628 (abstract).
  • 141
    Arts J, Caenepeel P, Degreef T et al. Randomized double-blind cross-over study evaluation the effect of intrapyloric injection of botulinum toxin on gastric emptying and symptoms in patients with gastroparesis. Gastroenterology 2005; 128: A81 (abstract).
  • 142
    Kim CH, Nelson DK. Venting percutaneous gastrostomy in the treatment of refractory idiopathic gastroparesis. Gastrointest Endosc 1998; 47: 6770.
  • 143
    Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol 2003; 98: 21229.
    Direct Link:
  • 144
    McCallum RW, Chen JDZ, Lin Z, Schirmer BD, Williams RD, Ross RA. Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998; 114: 45661.
  • 145
    Abell T, Custem EV, Abrahamsson H. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion 2002; 66: 20421.
  • 146
    Abell T, McCallum R, Hocking M et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003; 125: 4218.
  • 147
    Abell T, Lou J, Tabaa M, Batista O, Malinowski S, Al-Juburi A. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow up. J Parenter Enteral Nutr 2003; 98: 27781.
  • 148
    Lin Z, Forster J, Sarosiek I, McCallum RW. Treatment of gastroparesis by high-frequency gastric electrical stimulation. Diabetes Care 2004; 27: 10716.
  • 149
    Lin Z, McElhinney C, Sarosiek I, Forster J, McCallum R. Chronic gastric electrical stimulation for gastroparesis reduces the use of prokinetic and/or antiemetic medications and the need for hospitalizations. Dig Dis Sci 2005; 50: 132834.
  • 150
    Abell T, Al-Juburi A, Bashed H, Mirocha A. 13 years, 214 patients and over 5000 patient months: a long term report on gastric electric stimulation. Gastroenterology 2005; 128(4 Suppl. 2): A282 (abstract).
  • 151
    Oubre B, Luo J, Al-Juburi A, Voeller G, Familoni B, Abell TL. Pilot study on gastric electric stimulation on surgery-associated gastroparesis: long-term outcome. South Med J 2005; 98: 6937.
  • 152
    McCallum R, Lin Z, Wetzel P, Sarosiek I, Forster J. Clinical response to gastric electrical stimulation in patients with postsurgical gastroparesis. Clin Gastroenterol Hepatol 2005; 3: 4954.
  • 153
    Ayinala S, Batista O, Goyal A et al. Temporary gastric electrical stimulation with orally or PEG-placed electrodes in patients with drug refractory gastroparesis. Gastrointest Endosc 2005; 61: 45561.
  • 154
    Lin Z, Cocjin J, Sarosiek I, Roeser K, McCallum RW. Influence of high-frequency electrical stimulation on gastric electrical activity, autonomic function and symptoms in gastroparetic patients. Neurogastroenterol Motil 2005; 17: 4801.
  • 155
    Tack J, Coulie B, Van Custem E et al. The influence of gastric electrical stimulation on proximal gastric motor and sensory function in severe idiopathic gastroparesis. Gastroenterology 1999; 116: G4733 (abstract).
  • 156
    Cocjin J, Lin Z, Scoggan R, Sarosiek I, McCallum RW. Effects of high-frequency low-energy gastric electrical stimulation (Enterra device) on gastric distention and tone in gastroparetic patients. Gastroenterology 2005; 128: A136 (abstract).
  • 157
    McCallum RW, Dusing R, McMillin C et al. Fluoro-deoxyglucose (FDG) positron emission tomography (PET) in gastroparetic patients before and during gastric electrical stimulation (GES). Gastroenterolgy 2005; 128: A622 (abstract).
  • 158
    Hasler W. Nonoperative management of patients with gastroparesis referred for gastric electrical stimulator implantation. Neurogastroenterol Motil 2005; 17: 480 (abstract).
  • 159
    Skole KS, Panganamamula KV, Bromer MQ, Meilahn JE, Fisher RS, Parkman HP. Efficacy of gastric electric stimulation for gastroparesis refractory to medical therapy. Am J Gastroenterol 2002; 97: S48 (abstract).
  • 160
    Watkins PJ, Buxton-Thomas MS, Howard ER. Long-term outcome after gastrectomy for intractable diabetic gastroparesis. Diabet Med 2003; 20: 5863.
  • 161
    Karlstrom L, Kelly KA. Roux-Y gastrectomy for chronic gastric atony. Am J Surg 1989; 157: 449.
  • 162
    McCallum RW, Polepalle SC, Schirmer B. Completion gastrectomy for refractory gastroparesis following surgery for peptic ulcer disease. Dig Dis Sci 1991; 36: 155661.
  • 163
    Eckhauser RE, Conrad M, Knol JA, Mulholland MW, Colletti LM. Safety and long-term durability of completion gastrectomy in 81 patients with postsurgical gastroparesis syndrome. Am Surg 1998; 64: 7117.
  • 164
    Forstner-Barthell AW, Murr MM, Nitecki S et al. Near-total completion gastrectomy for severe postvagotomy gastric stasis. J Gastrointest Surg 1999; 3: 1521.
  • 165
    Kennedy WR, Navarro X, Goetz FC, Sutherland DE, Najarian JS. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990; 322: 10317.
  • 166
    Murat A, Pouliquen B, Cantarovich D et al. Gastric emptying improvement after simultaneous segmental pancreas and kidney transplantation. Transplant Proc 1992; 24: 855.
  • 167
    Hathaway DK, Abell T, Cardoso S, Hartwig MS, el Gebely S, Gaber AO. Improvement in autonomic and gastric function following pancreas-kidney versus kidney-alone transplantation and the correlation with quality of life. Transplantation 1994; 57: 81622.